NeuroSense Therapeutics Ltd.
NRSN | NASDAQ
$1.99
-$0.14 (-6.57%)
At close: Oct 30, 2026, 4:00 PM ET
$1.99
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 7:30 PM ET
Company Profile
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Key Executives
| Name | Position |
|---|---|
| Alon Ben-Noon | Co-Founder, Chief Executive Officer & Director |
| Niva Russek-Blum | Chief Technology Officer |
| Or Eisenberg | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 02, 2026 | 6-K | Filing |
| Sep 25, 2026 | 6-K | Filing |
| Sep 09, 2026 | 6-K | Filing |
| Aug 27, 2026 | 6-K | Filing |
| Aug 13, 2026 | 6-K | Filing |
| Aug 06, 2026 | 6-K | Filing |
| Jul 31, 2026 | EFFECT | Filing |
| Jul 31, 2026 | 6-K | Filing |
| Jul 31, 2026 | 6-K | Filing |
| Jul 30, 2026 | F-3/A | [Amend] Filing |
NeuroSense Therapeutics Ltd.
| Country | Israel |
| IPO Date | Dec 9, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Alon Ben-Noon |
Stock Details
| Ticker Symbol | NRSN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001875091 |
| CUSIP Number | M74240108 |
| ISIN Number | IL0011809592 |
| SIC Code | 2834 |
Recent News
- 2 months ago / prnewswire.comNeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
- 2 months ago / prnewswire.comNeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
- 3 months ago / prnewswire.comNeuroSense Issues CEO Letter to Shareholders
- 3 months ago / gurufocus.comNeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
- 3 months ago / prnewswire.comNeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
- 4 months ago / prnewswire.comNeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
- 4 months ago / gurufocus.comNeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
- 4 months ago / prnewswire.comNeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
Add to Watchlist
Select watchlists to add or remove NRSN